Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company dedicated to redefining psychiatric care through precision medicine. The company's core technology is its Precision Psychiatry Platform, which leverages artificial intelligence, electroencephalogram (EEG) data, genetics, wearable technology, and neurocognitive assessments to identify specific patient phenotypes. By characterizing these biological signatures, Alto aims to predict which patients are most likely to respond to its pipeline of novel drug candidates. The company's clinical-stage pipeline includes several oral small molecule therapies, such as ALTO-100 and ALTO-300 for major depressive disorder (MDD), as well as candidates targeting schizophrenia and post-traumatic stress disorder (PTSD). Headquartered in Los Altos, California, Alto Neuroscience advances its pharmacodynamically synergistic combinations through clinical trials to provide targeted alternatives to conventional psychiatric treatments.
